These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 30604493)

  • 41. Ten-Year Clinical Outcomes From a Trial of Three Limus-Eluting Stents With Different Polymer Coatings in Patients With Coronary Artery Disease.
    Kufner S; Joner M; Thannheimer A; Hoppmann P; Ibrahim T; Mayer K; Cassese S; Laugwitz KL; Schunkert H; Kastrati A; Byrne RA;
    Circulation; 2019 Jan; 139(3):325-333. PubMed ID: 30586724
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Three-year efficacy and safety of new- versus early-generation drug-eluting stents for unprotected left main coronary artery disease insights from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 trials.
    Cassese S; Kufner S; Xhepa E; Byrne RA; Kreutzer J; Ibrahim T; Tiroch K; Valgimigli M; Tölg R; Fusaro M; Schunkert H; Laugwitz KL; Mehilli J; Kastrati A
    Clin Res Cardiol; 2016 Jul; 105(7):575-84. PubMed ID: 26689707
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
    Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
    JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bifurcation treatment with novel, highly flexible drug-eluting coronary stents in all-comers: 2-year outcome in patients of the DUTCH PEERS trial.
    van der Heijden LC; Kok MM; Lam MK; Danse PW; Schramm AR; Jessurun GA; Tjon Joe Gin RM; van Houwelingen KG; Hautvast RW; Linssen GC; Sen H; Löwik MM; IJzerman MJ; Doggen CJ; von Birgelen C
    Clin Res Cardiol; 2016 Mar; 105(3):206-15. PubMed ID: 26329584
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical Events and Patient-Reported Chest Pain in All-Comers Treated With Resolute Integrity and Promus Element Stents: 2-Year Follow-Up of the DUTCH PEERS (DUrable Polymer-Based STent CHallenge of Promus ElemEnt Versus ReSolute Integrity) Randomized Trial (TWENTE II).
    Sen H; Lam MK; Löwik MM; Danse PW; Jessurun GA; van Houwelingen KG; Anthonio RL; Tjon Joe Gin RM; Hautvast RW; Louwerenburg JH; de Man FH; Stoel MG; van der Heijden LC; Linssen GC; IJzerman MJ; Tandjung K; Doggen CJ; von Birgelen C
    JACC Cardiovasc Interv; 2015 Jun; 8(7):889-99. PubMed ID: 26003019
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term (5-year) clinical evaluation of the Resolute zotarolimus-eluting coronary stent: The RESOLUTE US clinical trial.
    Kirtane AJ; Yeung AC; Ball M; Carr J; O'Shaughnessy C; Mauri L; Liu M; Leon MB
    Catheter Cardiovasc Interv; 2020 May; 95(6):1067-1073. PubMed ID: 31301219
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent.
    Kirtane AJ; Leon MB; Ball MW; Bajwa HS; Sketch MH; Coleman PS; Stoler RC; Papadakos S; Cutlip DE; Mauri L; Kandzari DE;
    JACC Cardiovasc Interv; 2013 Apr; 6(4):325-33. PubMed ID: 23523453
    [TBL] [Abstract][Full Text] [Related]  

  • 48. One-year clinical outcome of biodegradable polymer sirolimus-eluting stent in patients presenting with acute myocardial infarction: Insight from the ULISSE registry.
    Moscarella E; Ielasi A; Beneduce A; Ferrante G; Pivato CA; Chiarito M; Cappelletti A; Perfetti G; Magni V; Prati E; Falcone S; Pierri A; De Martini S; Montorfano M; Parisi R; Rutigliano D; Locuratolo N; Anzuini A; Calabrò P; Tespili M; Margonato A; Benassi A; Briguori C; Fabbiocchi F; Reimers B; Bartorelli A; Colombo A; Godino C
    Catheter Cardiovasc Interv; 2019 Dec; 94(7):972-979. PubMed ID: 31037840
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nobori-Biolimus-Eluting Stents versus Resolute Zotarolimus-Eluting Stents in Patients Undergoing Coronary Intervention: A Propensity Score Matching.
    Tantawy A; Ahn CM; Shin DH; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Hong MK
    Yonsei Med J; 2017 Mar; 58(2):290-295. PubMed ID: 28120558
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Zotarolimus-eluting Resolute Integrity versus everolimus-eluting Xience Xpedition stents in the management of very long (>30mm) de novo coronary artery stenosis.
    Patra S; Chakraborty RN; Pande A; Banerjee S; Jena M; Mandal PC; De SK; Khan A; Das SS; Ghosh D; Nag R
    Cardiovasc Revasc Med; 2017; 18(3):160-164. PubMed ID: 28017259
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Unrestricted use of 2 new-generation drug-eluting stents in patients with acute myocardial infarction: a propensity score-matched analysis.
    Chen KY; Rha SW; Wang L; Li YJ; Li GP; Poddar KL; Park JY; Choi CU; Park CG; Seo HS; Oh DJ; Jeong MH; Ahn YK; Hong TJ; Kim YJ; Hur SH; Seong IW; Chae JK; Cho MC; Bae JH; Choi DH; Jang YS; Chae IH; Kim CJ; Yoon JH; Chung WS; Seung KB; Park SJ;
    JACC Cardiovasc Interv; 2012 Sep; 5(9):936-45. PubMed ID: 22995881
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical Outcomes One Year and Beyond After Combination Sirolimus-Eluting Endothelial Progenitor Cell Capture Stenting During Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction.
    Sim HW; Thong EH; Tan HC; Low AF; Lee CH; Chan MY; Tay EL; Loh PH; Chan KH; Loh JP
    Cardiovasc Revasc Med; 2019 Sep; 20(9):739-743. PubMed ID: 30442536
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Final 5-year outcomes from the Endeavor zotarolimus-eluting stent clinical trial program: comparison of safety and efficacy with first-generation drug-eluting and bare-metal stents.
    Kandzari DE; Leon MB; Meredith I; Fajadet J; Wijns W; Mauri L
    JACC Cardiovasc Interv; 2013 May; 6(5):504-12. PubMed ID: 23602459
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Polymer-Free Biolimus-Eluting Stents or Polymer-Based Zotarolimus-Eluting Stents for Coronary Bifurcation Lesions.
    Gallone G; D'Ascenzo F; Ielasi A; Landra F; Stefanini GG; Di Biasi M; Mancone M; Tomai F; Infantino V; Rognoni A; Briguori C; Boccuzzi G; Smolka G; Chiarito M; Capodanno D; Chieffo A; Fabbiocchi F; Poli A; Tespili M; D'Urbano M; Giordano A; Escaned J; De Ferrari GM; Sardella G
    Cardiovasc Revasc Med; 2022 Feb; 35():66-73. PubMed ID: 33903036
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparing Stent Thrombosis associated with Zotarolimus Eluting Stents versus Everolimus Eluting Stents at 1 year follow up: a systematic review and meta-analysis of 6 randomized controlled trials.
    Bundhun PK; Yanamala CM; Huang WQ
    BMC Cardiovasc Disord; 2017 Mar; 17(1):84. PubMed ID: 28302055
    [TBL] [Abstract][Full Text] [Related]  

  • 56. One-year outcomes of consecutive patients treated by Endeavor zotarolimus and Resolute zotarolimus stents: the impact of polymer coating in drug-eluting stent technology.
    Talarico GP; Burzotta F; Trani C; Tommasino A; Niccoli G; Porto I; Leone AM; Mongiardo R; Schiavoni G; Crea F
    Catheter Cardiovasc Interv; 2013 Feb; 81(2):268-73. PubMed ID: 22639426
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Five-year outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease: final results from the ISAR-TEST 4 randomised trial.
    Kufner S; Byrne RA; Valeskini M; Schulz S; Ibrahim T; Hoppmann P; Schneider S; Laugwitz KL; Schunkert H; Kastrati A;
    EuroIntervention; 2016 Mar; 11(12):1372-9. PubMed ID: 25405657
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
    Kandzari DE; Mauri L; Popma JJ; Turco MA; Gurbel PA; Fitzgerald PJ; Leon MB
    JACC Cardiovasc Interv; 2011 May; 4(5):543-50. PubMed ID: 21596327
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Three-year patient-related and stent-related outcomes of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice (from the Multicenter Prospective EXCELLENT and RESOLUTE-Korea Registries).
    Lee JM; Park KW; Han JK; Yang HM; Kang HJ; Koo BK; Bae JW; Woo SI; Park JS; Jin DK; Jeon DW; Oh SK; Park JS; Kim DI; Hyon MS; Jeon HK; Lim DS; Kim MG; Rha SW; Her SH; Hwang JY; Kim S; Choi YJ; Kang JH; Moon KW; Jang Y; Kim HS
    Am J Cardiol; 2014 Nov; 114(9):1329-38. PubMed ID: 25217457
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization: 3-Year Outcomes From the Randomized BIOFLOW V Trial.
    Kandzari DE; Koolen JJ; Doros G; Garcia-Garcia HM; Bennett J; Roguin A; Gharib EG; Cutlip DE; Waksman R;
    JACC Cardiovasc Interv; 2020 Jun; 13(11):1343-1353. PubMed ID: 32499026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.